CryoLife begins defence against class actions
This article was originally published in Clinica
Beleaguered tissue implants and surgical adhesive company CryoLife (Kennesaw, Georgia) has begun to mount a defence of recent actions that have attracted class action lawsuits. The company has appointed King & Spaulding to counter claims by two law firms (see Clinica No 1015, p 1) that it issued misleading statements between August 2000 and June 2002, including one referring to the number of FDA warning letters it had received.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.